Navigation Links
Moleac Announces the Beneficial Effect of NeuroAiD (TM) (MLC 901) in Protecting the Brain Against Global Ischemia
Date:6/27/2011

SINGAPORE, June 27, 2011 /PRNewswire-Asia/ -- In June 2011, "Neuropharmacology" published a paper establishing NeuroAiD's reparative effects on global cerebral ischemia. Global cerebral ischemia is subsequent to cardiac arrest, reversible severe hypotension or other situations depriving the brain of oxygen and glucose. It results in residual neurologic deficits, ranging from mild cognitive impairment to severe neurological deficits, for which there is no treatment to date.

The research paper shows that NeuroAiD post global ischemia protects the neurons against ischemic injury in the CA1 region of the hippocampus which plays a critical role in the consolidation of information from short-term to long-term memory. In animal models, NeuroAiD inhibits neuronal cell death and protects neurons against DNA fragmentation by activating phosphorylation of the AKT protein and reducing oxidative stress. This corresponds to the better recovery of cognitive and motor deficits observed post stroke in clinical experiences.  

This study builds on previous research conducted in 2010 at the Institute of Molecular Pharmacology of the CNRS (French National Centre for Scientific Research) establishing NeuroAiD's neuroprotective and neuroreparative properties, and explaining the neurological recovery seen in post stroke patients.  The results established that NeuroAiD triggers the synthesis of the Brain Derived Neurotrophic Factor (BDNF), which is known to promote neuroplasticity. Indeed, NeuroAiD induces neurogenesis in rodent and human cells, and stimulates the development of new neuronal circuits of information by promoting cell proliferation and the development of dense axonal and dendritic networks. The recent data further confirms the neuroprotective effect of NeuroAiD and encourages prescribing it as soon as possible after a stroke so as to ensure a higher level of protection.

The lead researchers behind this new paper are Catherine Heurteaux and Michel Lazdunski, world-renowned specialists in pharmacology and neuroscience, who supervised a team of experts in cerebrovascular pathologies and therapeutics from the Institute of Molecular and Cellular Pharmacology at the CNRS in France.

Previous trials and clinical reports conducted in Asia have already evidenced NeuroAiD's safety and efficacy in post stroke rehabilitation, even when taken several months after the stroke's onset. This paper comes after the publication of three clinical peer reviewed papers in the first half of 2011. Firstly, the European Journal of Internal Medicine published a paper establishing a significant increase of Cerebral Blood Flow velocity after 3 months in stroke patients treated with NeuroAiD as compared to placebo. These results, in matching a better functional outcome, suggested increased angiogenesis and microcirculation activity. Secondly, Neuronal Regeneration Research published a paper suggesting that NeuroAiD may increase the recovery of vision deficits in post stroke Homonymous Hemianopsia patients. The patients in the NeuroAiD group demonstrated a 50% increase in therapeutic effects as compared to the Piracetam group. Lastly, Stroke Research and Treatment published a double-blind placebo-controlled clinical trial which was conducted on 150 patients having suffered from stroke less than 3 months ago. NeuroAiD showed a better motor recovery than placebo, and was safe as an add-on to standard ischemic stroke medications, especially in severe and moderate cases.

"This is good news for the patients", commented David Picard, CEO of Moleac. "The number of publications on NeuroAiD since the beginning of the year shows increased interest and reach for NeuroAiD. The latest papers further confirm how NeuroAiD benefits post stroke patients in cognitive and motor recovery. There is a strong urge for us to expand our clinical work to address the needs of post-cardiac arrest patients. In Europe alone, 350,000 people suffer cardiac arrest and many of them are left to cope with cognitive disabilities. For Picard to conclude: "By leveraging our considerable pharmacological research strengths along with extensive clinical studies, we are happy to make new breakthroughs in a broad range of neurologic disorders. We will dedicate our efforts in further investigating the potential of NeuroAiD in treating neurological deficits induced by global ischemia, which could present an interesting strategy for the patients who undergo cardiac arrest."

About Moleac
http://www.moleac.net
Moleac is a Singapore-based biopharmaceutical company dedicated to finding and developing new medicines for the unmet needs of patients worldwide.

About NeuroAiD™
http://www.NeuroAiD™.com
NeuroAiD™ is a stroke treatment to help stroke patients achieve a faster and better recovery. NeuroAiD is derived from natural components, carefully selected for their efficacy and absence of side effects. It currently reaches out to patients in over 25 countries.

Contact details:
Kasia Kaminska
Tel: +65-8533-0652
Email: kasia.kaminska@moleac.net


'/>"/>
SOURCE Moleac
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. NIAID announces 25 new awards to develop radiation countermeasures
2. Aware Announces Q3 2008 Earnings Conference Call
3. Governor Doyle announces historic genomic research collaboration
4. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
5. NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders
6. Parkinsons Disease Foundation announces award of $150,000
7. Jefferson Department of Surgery announces new pancreas tumor registry
8. NAS announces initiative to connect entertainment industry with top experts
9. Elsevier announces winners of 3rd Annual Scopus Young Indian Scientist Award
10. VUANCE Announces Crime Scene Security and Evidentiary Tracking Development Project
11. WCC Announces Version 6 of its ELISE Smart Search and Match Platform for Employment and Biometric Matching
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
Breaking Biology Technology: